Goldman Sachs downgraded Luye Pharma to Sell from Neutral with a price target of HK$3.73, up from HK$3.68. The firm sees modest product sales growth in the coming years and views earnings improvement from potential debt pay-down as reflected in the share price, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>